ClinicalTrials.gg
CompletedNCT06794996AMPLIFIEDUpdated Aug 20, 2026

Inaxaplin in Participants With Proteinuric APOL1 Mediated Kidney Disease With or Without Comorbidities

A Phase 2 interventional study of Inaxaplin in Proteinuric Kidney Disease, sponsored by Vertex Pharmaceuticals Incorporated. Completed at 35 sites in United States. Open to participants aged 18 Years to 67 Years. Per ClinicalTrials.gov, last updated 2026-08-20.

Sponsored by Vertex Pharmaceuticals Incorporated · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
42
Allocation
Not applicable
Ages
18 Years to 67 Years
Sex
All
01

Study summary

The purpose of the study is to evaluate the efficacy, safety, and tolerability of Inaxaplin (IXP) in participants with proteinuric APOL1- mediated kidney disease (AMKD).

02

Conditions studied

  • Proteinuric Kidney Disease

Keywords

  • APOL1-mediated kidney disease (AMKD)
03

In context

Lead sponsor

Vertex Pharmaceuticals Incorporated is the lead sponsor of 249 studies on the registry; 17 are open to participants now.

Of its 107 completed or terminated interventional studies of FDA-regulated products, 54 (50%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 67 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Participant has an APOL1 genotype of G1/G1, G2/G2, or G1/G2 obtained with a Vertex designated clinical study assay
  • Estimated (eGFR) of greater than or equal to (≥) 25 milliliter per minute (mL/min)/1.73m\^2 at screening

Key Exclusion Criteria:

  • Evidence of Focal Segmental Glomerulosclerosis (FSGS) with a known cause other than due to APOL1 risk variants
  • Uncontrolled hypertension

Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
42 participants (actual)

Study arms

  • Experimental
    IXP (Inaxaplin)

    Participants with proteinuric APOL1-mediated kidney disease (AMKD) with or without the comorbidity of Type 2 diabetes mellitus (T2DM) will receive a single dose of IXP once daily, for 13 weeks.

    Drug: Inaxaplin

Interventions

  • Tablets for Oral Administration.

    Also known as: IXP, VX-147

06

What researchers measure

Primary outcomes

  1. Percent Change in Urine Albumin-Creatinine Ratio (UACR)

    Time frame: Baseline and At Week 13

Secondary outcomes

  1. Safety and Tolerability as Assessed by Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Time frame: From Baseline Up To Week 17

07

Study locations

35 sites
  • Nephrology Consultants, LLC
    Huntsville, Alabama 35805, United States
  • Foundation for Sickle Cell Disease Research, LLC
    Hollywood, Florida 33023, United States
  • South Florida Research Institute
    Lauderdale Lakes, Florida 33313, United States
  • Schiff Center for Liver Diseases
    Miami, Florida 33136, United States
  • CTR Oakwater, LLC
    Orlando, Florida 32806, United States
  • Renal Associates, LLC
    Columbus, Georgia 31904, United States
  • Georgia Nephrology - Decatur
    Decatur, Georgia 30030, United States
  • Javara Inc./Privia Medical Group Georgia, LLC - Fayetteville
    Fayetteville, Georgia 30214, United States
  • Georgia Nephrology
    Lawrenceville, Georgia 30046, United States
  • Javara Inc. /Privia Medical Group Georgia, LLC - Savannah
    Savannah, Georgia 31406, United States
  • Renal Associates of Baton Rouge
    Baton Rouge, Louisiana 70808, United States
  • LCMC Health
    Metairie, Louisiana 70006, United States
  • Ochsner Medical Center - New Orleans - Nephrology
    New Orleans, Louisiana 70121, United States
  • Northwest Louisiana Nephrology, LLC - Shreveport
    Shreveport, Louisiana 71101, United States
  • Javara Inc./Privia Medical Group, LLC MidAtlantic-Silver Spring, MD
    Silver Spring, Maryland 20901, United States
  • Nephrology Associates, P.C.
    Columbus, Mississippi 39705, United States
  • Nephrology and Hypertension Associates, LTD
    Tupelo, Mississippi 38801, United States
  • DaVita Kidney Care - Las Vegas
    Las Vegas, Nevada 89107, United States
  • Saint Michael's Medical Center - Peter Ho Memorial Clinic
    Newark, New Jersey 07102, United States
  • Rutgers Doctors Office Center
    Newark, New Jersey 07103, United States
  • Scott Research, Inc.
    Laurelton, New York 11413, United States
  • NYC Health + Hospital/Harlem
    New York, New York 10037, United States
  • North Carolina Nephrology P.A. - Cary Office
    Cary, North Carolina 27511, United States
  • UNC Clinical and Translational Research Center
    Chapel Hill, North Carolina 27599-7155, United States
  • Duke University Hospital - Children's Health Center
    Durham, North Carolina 27710, United States
  • Eastern Nephrology Associates - New Bern Office
    New Bern, North Carolina 28562, United States
  • Lewis Katz School of Medicine at Temple University - Section of Nephrology
    Philadelphia, Pennsylvania 19140, United States
  • Columbia Nephrology Associates, PA
    Columbia, South Carolina 29203, United States
  • Carolina Nephrology, PA
    Spartanburg, South Carolina 29306, United States
  • Dallas Renal Group - 2
    Dallas, Texas 75230, United States
  • Dallas Renal Group - 1
    Dallas, Texas 75237, United States
  • Dallas Nephrology Associates - Dallas Landry Office
    Dallas, Texas 75246, United States
  • UTSW Medical Center - Nephrology
    Dallas, Texas 75390, United States
  • Prolato Clinical Research Center
    Houston, Texas 77054, United States
  • Tks Research, P.L.L.C.
    Norfolk, Virginia 23504, United States
08

References and documents

Individual participant data

Plan to share: No — Details on Vertex data sharing criteria and process for requesting access can be found at: https://www.vrtx.com/our-science/clinical-trials-data-sharing/

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2025 to primary completion in Jul 2026, 17 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 23, 2025
First posted
Jan 27, 2025
StartActual
Feb 4, 2025
Primary completionActual
Jul 20, 2026
CompletionActual
Jul 20, 2026
Last update
Aug 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06794996
Responsible party
Sponsor
First posted
Jan 27, 2025
Start date
Feb 4, 2025
Primary completion
Jul 20, 2026
Completion
Jul 20, 2026
Last update
Aug 20, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Inaxaplin

Start the discussion